Delving into the Latest Updates on Tetanus vaccine (Seasons Biologicals) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms

Tetanus vaccine (adsorbed)

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesOther Diseases

Active Indication-

Inactive Indication

Tetanus

Originator Organization

331 Holt Lane Operations LLC

Active Organization-

Inactive Organization

331 Holt Lane Operations LLC

Drug Highest PhasePendingPhase 2/3

First Approval Date-

Regulation-

Login to view timeline

The conventional inactivated tetanus toxin plays an instrumental role in preventing tetanus. Nevertheless, the challenges associated with its production process, the potential for adverse reactions, and reduced effectiveness in vulnerable populations such as neonates and the elderly rise the need for a novel tetanus toxin vaccine. Recombinant subunit vaccine offer a viable solution, and the tetanus toxin fragment C (TTFC) is emerging as a promising candidate. In this study, through spontaneous isopeptide bond formation we conjugated the recombinant TTFC to self-assembled mi3 nanoparticle, which derived from an optimized KDPG aldolase, and generated the TTFC-mi3 protein nanoparticle vaccine. We found that TTFC-mi3 is stable, uniform spherical nanoparticles. Comparing with the free TTFC alone, TTFC-mi3 enhances the uptake and subsequent activation of dendric cells (DCs). In addition, a single dose of adjuvant-free TTFC-mi3 elicited a more rapid and potent protective immunity in mice. Moreover, TTFC-mi3 is of favorable safety in vitro and in vivo. Our findings indicate that TTFC-mi3 is a rapid-response, non-aluminum-adjuvanted vaccine against tetanus.

01 Jul 2024·Journal of Hazardous Materials

Per- and polyfluoroalkyl substances and human health outcomes: An umbrella review of systematic reviews with meta-analyses of observational studies

Review

Author: Li, Xiao-Ying ; Sun, Jia-Nan ; Zhang, Ying-Ying ; Xu, He-Li ; Yin, Jia-Li ; Zheng, Wen-Rui ; Wei, Yi-Fan ; Wang, Jia-Yi ; Jia, Ming-Qian ; Liu, Fang-Hua ; Gong, Ting-Ting ; Liu, Jia-Cheng ; Wu, Qi-Jun ; Liu, Jia-Xin ; Liu, Ke-Xin ; Xing, Wei-Yi ; Song, Xin-Jian ; Shan, Li-Shen ; Chen, Xing ; Li, Yi-Zi ; Liu, Chuan

BACKGROUNDAlthough evidence on the association between per- and polyfluoroalkyl substances (PFASs) and human health outcomes has grown exponentially, specific health outcomes and their potential associations with PFASs have not been conclusively evaluated.METHODSWe conducted a comprehensive search through the databases of PubMed, Embase, and Web of Science from inception to February 29, 2024, to identify systematic reviews with meta-analyses of observational studies examining the associations between the PFASs and multiple health outcomes. The quality of included studies was evaluated using the A Measurement Tool to Assess Systematic Reviews (AMSTAR) tool, and credibility of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) criteria. The protocol of this umbrella review (UR) had been registered in PROSPERO (CRD 42023480817).RESULTSThe UR identified 157 meta-analyses from 29 articles. Using the AMSTAR measurement tool, all articles were categorized as of moderate-to-high quality. Based on the GRADE assessment, significant associations between specific types of PFASs and low birth weight, tetanus vaccine response, and triglyceride levels showed high certainty of evidence. Moreover, moderate certainty of evidence with statistical significance was observed between PFASs and health outcomes including lower BMI z-score in infancy, poor sperm progressive motility, and decreased risk of preterm birth as well as preeclampsia. Fifty-two (33%) associations (e.g., PFASs and gestational hypertension, cardiovascular disease, etc) presented low certainty evidence. Additionally, eighty-five (55%) associations (e.g., PFASs with infertility, lipid metabolism, etc) presented very low certainty evidence.CONCLUSIONHigh certainty of evidence supported that certain PFASs were associated with the incidence of low birth weight, low efficiency of the tetanus vaccine, and low triglyceride levels.

01 May 2024·Journal of Infection and Chemotherapy

Autopsy of tetanus with foot gangrene as portal of entry

Author: Mizushima, Ryo ; Ohmagari, Norio ; Nomoto, Hidetoshi ; Yamada, Gen ; Yamamoto, Kei ; Kurokawa, Masami ; Kawashima, Akira ; Okumura, Nobumasa ; Wakatsuki, Miyu ; Sakurai, Ayana

Non-traumatic chronic skin lesions are the second most common cause of tetanus. Herein, we describe an 85-year-old woman who presented with a chronically infected skin lesion. She developed tetanus while in hospital and died of respiratory failure, after refusing mechanical ventilation. Routine immunization against tetanus began in Japan during 1968; hence many people born before 1968 are unvaccinated. Mortality due to tetanus is high and the proportion with protective antibodies is low in older adults. Therefore, we recommend tetanus vaccination for older persons in Japan who have chronic skin lesions and have never been vaccinated.

100 Deals associated with Tetanus vaccine (Seasons Biologicals)

Login to view more data